17,261 trials
Idiopathic Polypoidal Choroidal Vasculopathy
Primary: Number of Participants With >15 ETDRS Letter Loss at Month 3 — 0 Participants
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Uterine Cancer
Primary: Cycles With Hematologic Toxicities — 11; 14; 6; 0 Cycles
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Chronic Obstructive Pulmonary Disease Moderate
Primary: Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing — 0.477; 0.500; 0.373 Liters — p=0.0022
Psoriasis · Plaque Psoriasis
Primary: Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs — 27; 32; 0; 0 TEAEs
Pancreatic Cancer
Primary: Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm — 0 Participants
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed — 25.5; 25.6; 25.5; 25.8 score on a scale
Rosacea
Primary: Change in Inflammatory Lesion Counts — -1.4; 2.9 Number of lesions
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Hematologic Malignancies
Primary: Safety Measures — 0 participants
Multiple Sclerosis
Primary: Number of Subjects With Active (New or Enlarging) T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) at Month 12 — 4; 7 Participants — p=0.271
Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 6; 1 number of patients without DLT
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 98.9; 97.8 Percentage of Participants